Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Feb 7;210(2):306–310. doi: 10.1093/infdis/jiu087

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

PMC Copyright notice

Figure 1. — Superoxide dismutase 1 (SOD1) is a biomarker for therapeutic failure in cutaneous leishmaniasis. A, SOD1 measurements in plasma samples from 20 healthy controls, 58 patients with localized cutaneous leishmaniasis (LCL) due to Leishmania braziliensis), 10 patients with LCL due to Leishmania amazonensis, and 8 patients with diffuse cutaneous leishmaniasis (DCL) due to L. amazonensis. Box plots represent the median and interquartile range of each group. P < .001, by the Kruskal–Wallis test; and ***P < .001, by the Dunn posttest, for healthy controls vs patients with LCL due to L. braziliensis; **P < .01, by the Dunn posttest, for healthy controls vs patients with LCL due to L. amazonensis; and ***P < .001, by the Mann–Whitney U test, for patients with LCL due to L. amazonensis vs patients with DCL. B, Plasma SOD1 level significantly discriminates patients with LCL due to L. amazonensis from patients with DCL due to L. amazonensis (area under the receiving operating characteristic [ROC] curve, 0.95; ***P = .001). C, SOD1 measurements in plasma samples from patients with LCL due to L. braziliensis, classified according to number of treatment cycles (P = .0069, by the Kruskal–Wallis test; **P < .001, by the Dunn posttest). Three outliers (by the Tukey test) are shown as single dots. D, Plasma SOD1 level significantly predicts therapeutic response in patients with LCL due to L. braziliensis (success is defined as achievement of cure after 1 treatment cycle; failure is defined as lack of cure after >2 treatment cycles; area under the receiving operating characteristic curve, 0.83; ***P = .00025, without outliers, as in panel C).